IPO
PCI Biotech, a cancer focused biopharmaceutical company announces its third quarter 2019 result.
Certain of Recipharm’s larger institutional shareholders, Första AP-fonden, Lannebo Fonder and Fjärde AP-fonden, support the cash offer for Consort Medical and have undertaken to fully support and vote in favour of a rights issue at a forthcoming general meeting of Recipharm and have also undertaken to subscribe for an amount corresponding to at least their respective pro rata share in a rights issue of SEK 2,000 million.
With the Thanksgiving holiday fast-approaching in the United States, some investors are giving their thanks to five different pharma companies that became available on the stock exchange this month with an initial public offering.
Motif Bio plc announces that formal notice was given by the Company to Nasdaq on November 25, 2019 of the intention to voluntarily delist the Company’s American Depository Shares and listed warrants from the Nasdaq Capital Market.
Alzheimer’s Research UK welcomes the Conservatives’ pledge to double investment in dementia research as a ‘step in the right direction’.
Fortress Biotech, Inc. announced that it has priced an underwritten public offering of 262,500 shares of its 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock at a price of $20 per share, with expected gross proceeds to Fortress of approximately $5.3 million.
Sonoma Pharmaceuticals, Inc. announced the launch of a “best efforts” public offering of shares of its common stock.
Resverlogix Corp. announces a warrant exercise incentive program designed to encourage the early exercise of 15,593,428 warrants to purchase common shares of the Company.
Indus Holdings, Inc. announced that it has changed the date of its previously announced earnings release and earnings call.
Bio-Path Holdings, Inc., a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, announced the closing of its previously announced offering.
PRESS RELEASES